Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst
ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
